Old Articles: <Older 8561-8570 Newer> |
|
Pharmaceutical Executive March 1, 2013 Ben Comer |
Brand of the Year: Januvia When Merck's Januvia received its first regulatory approval, in Mexico in 2006, no one predicted its long-term success. In 2012, the company's diabetes franchise became the highest-selling product family in Merck's 122-year history. |
Pharmaceutical Executive March 1, 2013 Ken Getz |
Building Clinical Trial Awareness for Patients: Why Not Try the Pharmacist? The author explains how building a stakeholder outreach agenda around the community pharmacist can lead to a better outcome in managing the complex ins and outs of a trial protocol. |
Pharmaceutical Executive March 1, 2013 Sillup et al. |
Back in the News Big Pharma takes a fresh licking in our latest audit of US press coverage of business and policy issues. |
Pharmaceutical Executive March 1, 2013 Desai & Anbil |
Specialty Service Programs: Gearing up for Next Generation Technologies Innovation in hub program design for patient scrip data and clinical support services can lead to increased market share in the hotly contested specialty medicine space. |
Pharmaceutical Executive March 1, 2013 Jill Wechsler |
Another Round of FDA Legislation? Pressure for action on key enforcement and regulatory issues may prompt congressional action this year. |
Pharmaceutical Executive March 1, 2013 Keeling & Paz |
Early Engagement with Medical Laboratories Timely engagement is the key to expanding the use of companion diagnostics. |
Pharmaceutical Executive March 1, 2013 Al Topin |
Less Selling, More Time What can happen when pharmaceutical reps focus on the physician-patient conversation? |
Pharmaceutical Executive March 1, 2013 |
Who's Really in Charge of European Drug Registration? The European Commission blocks the authorization of a life-saving liver drug outside of France. |
Pharmaceutical Executive March 1, 2013 Bonifant & Setrakianis |
Test and Learn: Making Confident Decisions on the Commercial Side Companies that adopt this new methodology will have a longstanding competitive advantage over those companies conducting business as usual. |
Pharmaceutical Executive March 1, 2013 Forcellina & Akannac |
Embedding Market Access in Today's Pharma Business Model A proactive approach to talent and organization planning is the hidden trump card in prevailing with payers. |
<Older 8561-8570 Newer> Return to current articles. |